

Aurobindo Pharma receives FDA approval for Polymyxin B for Injection

06 April 2016 | News | By BioSpectrum Bureau

Aurobindo Pharma receives FDA approval for Polymyxin B for Injection



Aurobindo Pharma is pleased to announce that the company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Polymyxin B for Injection USP, 500,000 units/vial. This product is expected to be launched in Q2 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Polymyxin B for Injection USP, 500,000 units/vial of Eurohealth International Sarl.

Polymyxin B for Injection is an Anti-Infective used in the treatment of infections of the urinary tract, meninges, bloodstream and eye caused by susceptible strains of *Pseudomonas aeruginosa*. The approved product has an estimated market size of \$ 7.6 million for the twelve months ending February 2016 according to IMS.